Global Biologics Market: Size, Trends & Forecast (2019-2023 Edition)
The report includes a brief regional analysis of North America, South America, Europe, Asia Pacific and Middle East & Africa with their actual and forecasted market size. Under competitive landscape, key competitors in the market.
By: Daedal Research
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biologics market has also been forecasted for the years 2019-2023, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Abbvie Inc., Samsung Electronics (Samsung Biologics), F. Hoffmann La Roche and Amgen Inc. are some of the key players operating in the global biologics market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the respective companies are provided.
1. Abbvie Inc
2. Samsung Electronics (Samsung Biologics)
3. F.Hoffmann La Roche
4. Amgen Inc.
1. North America
2. South America
3. Europe (Western and Eastern Europe)
4. Asia Pacific (China)
5. Middle East and Africa
Pharmaceutical industry is engaged in the discovery, manufacturing and marketing of pharmaceutical drugs such as legal drugs, vaccines, biologics and a large number of medical devices such as infusion pump, pacemakers, prosthetics, implantable defibrillators etc. Pharmaceutical drugs and devices are subjected to various laws and regulations governing their patent, safety, and efficacy.
Large molecules are mostly made of cells or other living organisms and are used to produce therapeutic proteins or biological molecules. Drugs made up of large molecules are popularly known as biotech drugs, biologics or biopharmaceuticals. The major biologics blockbusters currently available in the market are Humira, Remicade, Enbrel, Avastin and Herceptin.
The global biologics market has increased over the years and projections are made that the market would grow at a steady pace in the next four years i.e. 2019-2023.
Yet the market faces some restraints which are obstructing the growth of the market. Some of the major challenges faced by the industry are emergence of biosimilars, high cost of biologics, lack of oral absorption and operational challenges.
For further details, kindly visit :
(Business Development Manager)
Address: 36 SFS Flats
Mail ID - info@daedal-